検索結果

役社長：吉田周平、以下「当社」 ）は、2026 年 3 月 15 日にイオンモール仙台上杉で開催される「GREEN CARE Fes! 2026」 （主催：東北大 学 COI‑NEXT「Vision to Connect」拠点）にブース出展いたします。 本イベントは、世界緑内障週間に合わせ、緑内障を含む眼の健康を中心に、さまざまな健康チ ェックや体験を通じて、日常の健康意識を高めることを目的とした...

ical devices by installing image sharpening the algorithm developed by Logic and Design Co., Ltd. into electronic medical record system and image filing system developed by Beeline Co., Ltd. We aim to...

, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces that it has entered into a LicensingAgreement for Corneal Esthesiometer Brill in Japan with Brill International (Headquart...

Publications | Research & Development | SENJU Pharmaceutica

cebo-Controlled Phase 1/2 Study of a TRPV1 Antagonist SJP-0132 in Participants With Dry Eye Disease Tomoyuki Wada1, Kazunori Omatsu1, Stephen C. Pflugfelder2 1: Senju Pharmaceutical Co., Ltd, Hyogo, J...

R&D Pipeline | Research & Development | SENJU Pharmaceutica

PROGRESS OF DEVELOPMENT Disclosuring of information after Phase 1 DrugIndicationStatus (Region) SJP-0132Dry eyeApproval（Japan） PranoprofeninflammationApplication under review (Vietnam) SJP-0132Dry eye